Vaccines and Immune System

Provenge prostate cancer vaccine linked to longer survival for asymptomatic hormone refractory stage -- UCSF study. June 28, 2006.

Adoptive Immunotherapy - Steps Toward Overcoming Biological Obstacles to Cell Therapy for Cancer February 16, 2006

Immune Stimulants May Help Antibody-Based Drugs Fight Cancer Jan 1, 2006

Combination Hormone/Vaccine Therapy for Prostate Cancer May Benefit Patients Whose Disease Returns July 25, 2005

A cancer vaccine combined with hormone-deprivation therapy can help patients with recurrence of prostate cancer. This is the result of a Phase II clinical trial. The vaccine tested consisted of recombinant vaccinia viruses containing the PSA and B7.1 costimulatory genes as prime vaccinations, and avipox-PSA as boosters.

Adding a prostate cancer vaccine to hormone therapy extended time to disease progression by nearly 14 months for men with recurrent prostate cancer compared to 9.9 months for vaccine alone and 7.6 months for hormone therapy alone.

New Breast Cancer Vaccine Trial to Target Early-Stage Cancers August 3, 2005

A new breast cancer vaccine trial will focus on patients with non-metastatic disease. While most cancer vaccine trials have focused on patients with late-stage cancer that has spread from the initial tumor site, researchers believe giving a vaccine earlier may produce a more powerful response to the cancer from the patient's immune system.

Cell Genesys Initiates Second Phase 3 Clinical Trial Of GVAX® Vaccine For Prostate Cancer July 5, 2005

Cell Genesys, Inc. (Nasdaq: CEGE) today announced the initiation of a second multicenter Phase 3 clinical trial of GVAX® vaccine for prostate cancer in patients with metastatic hormone-refractory prostate cancer.

This Phase 3 trial for hormone-refractory prostate cancer patients with radiologic evidence of metastatic disease will test GVAX plus taxotere against taxotere plus prednisone.

The first Phase 3 trial, which started in July 2004, is enrolling chemotherapy naïve, asymptomatic patients without cancer-related pain and is comparing GVAX® vaccine to Taxotere® chemotherapy plus prednisone.

Provenge Vaccine "Significantly Improves" Survival In Men With Advanced Prostate Cancer February 17, 2005

Dendreon Corporation announced today that Provenge®, the Company's investigational vaccine for the treatment of prostate cancer, "significantly improved survival" in men with asymptomatic, metastatic androgen-independent (hormone-refractory) prostate cancer when compared to patients receiving placebo.....

MICs shed light on prostate cancer August 16, 2004.

Usual immune system role of a molecule is counteracted by shedding in prostate cancer

The body's immune system has built in anti-tumor mechanisms. Cancers don't form unless the tumor cells develop the means to avoid being attacked by this defense mechanism.

Counseling Boosts Immunity in Breast Cancer Patients September 22, 2004

Breast cancer patients gained a stronger immune system from psychological counseling that reduced worry and encouraged healthier diets and reduced smoking.

Regular psychological counseling for breast cancer patients may do more than just lower their stress and anxiety. A new study says the right kind of intervention can also mean healthier diets, reduced smoking, and most surprising of all, a stronger immune system.

Gvax Prostate Cancer Vaccine Demonstrates Antitumor Activity December 11, 2000

Cell Genesys, Inc. reported that the company's Gvax® prostate cancer vaccine demonstrated antitumor activity in an initial Phase II trial in patients with advanced metastatic prostate cancer who have failed hormone therapy.

This page last edited by J. Strax, Aug 6, 2005.

Information on this website is not intended as medical advice nor to be taken as such. Consult qualified physicians specializing in the treatment of prostate cancer. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained on this website.

About Us | Site Archive | Content Policy/Disclaimer | Privacy Policy